Clinical Application of Recombinant Human Endostatin in Postoperative Early Complementary Therapy on Patients with Non-small Cell Lung Cancer in Chinese Mainland

Zhu, Qiang; Zang, Qi; Jiang, Zhong-Min; Wang, Wei; Cao, Ming; Su, Gong-Zhang; Zhen, Tian-Chang; Zhang, Xiao-Tian; Sun, Ning-Bo; Zhao, Cheng

추천

검색

자료유형: 학술저널

저자정보: Zhu, Qiang (Department of Thoracic Surgery, The Affiliated Qianfoshan Hospital of Shandong University) Zang, Qi (Department of Thoracic Surgery, The Affiliated Qianfoshan Hospital of Shandong University) Jiang, Zhong-Min (Department of Thoracic Surgery, The Affiliated Qianfoshan Hospital of Shandong University) Wang, Wei (Department of Thoracic Surgery, The Affiliated Qianfoshan Hospital of Shandong University) Cao, Ming (Department of Thoracic Surgery, The Affiliated Qianfoshan Hospital of Shandong University) Su, Gong-Zhang (Department of Thoracic Surgery, The Affiliated Qianfoshan Hospital of Shandong University) Zhen, Tian-Chang (Department of Thoracic Surgery, The Affiliated Qianfoshan Hospital of Shandong University) Zhang, Xiao-Tian (Weifang Medical University) Sun, Ning-Bo (Weifang Medical University) Zhao, Cheng (Shandong University School of Medicine)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제16권 제9호

발행연도: 2015.1

수록면: 4,013 - 4,018 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Objective: To explore the clinical application of recombinant human endostatin (Endostar) in the treatment of patients with non-small cell lung cancer (NSCLC) in Chinese mainland. Materials and Methods: A total of 75 patients diagnosed as NSCLC were randomly divided into control group (37 cases) and treatment group (38 cases). Control group was treated with postoperative complementary chemotherapy containing two-agent platinum protocol on postoperative d21, 3 weeks as a cycle, for totally 4~6 cycles. On this basis, treatment group was added with Endostar $7.5mg/m^2$ on postoperative d8~9, 3~4 h/time, qd, 14 weeks as a cycle, for totally 4 cycles. The interval between every two cycles was 7 d. The 5-year progression-free survival (PFS), 5-year survival time and complications in both groups were observed. Results: Compared with control group, the average PFS increased evidently in treatment group by 9.8 months (41.6 months vs. 31.8 months), and there was significant difference (P<0.05). And the median PFS was 42.5 months in treatment group, obviously longer than that in control group (33.7 months) by 8.8 months (P<0.05). Additionally, the 5-year overall survival rate (OS), average survival time and median survival time (MST) were 47.4%, 50.1 months and 59.3 months in treatment group, significantly higher than the 29.7%, 42.1 months and 43.5 months in control group (P<0.05). Only 1 patient showed poor healing of surgical wound in treatment group, but no surgery-associated complication was found in control group. Moreover, the postoperative complementary therapy-connected complication rates were 63.2% (24/38) and 59.5% (22/37) in treatment group and control group respectively, but there was no significant difference (P>0.05). Conclusions: The application of Endostar combined with sensitive platinum-contained chemotherapeutic agents in the postoperative complementary chemotherapy can be widely used in clinic because it can significantly prolong the long-term survival time of patients with NSCLC.

#Non-small cell lung cancer #recombinant human endostatin #postoperative complementary chemotherapy #progression-free survival #overall survival rate

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!